Lexicon Genetics News (NASDAQ:LEXG)
| Latest Lexicon Genetics News Headlines | | Date | Time | Source | | | 04/26/2007 | 6:30AM | PRNUS | Lexicon Genetics Changes Name to Lexicon Pharmaceuticals as Drug Development Pipeline Progresses
Lexicon Name Change Approved, Accompanied by New Stock Ticker
THE WOODLANDS, Texas, April 26 /PRNewswire-FirstCall/ -- Lexicon Genetics Incorporated (NASDAQ:LEXG) today announced that its proposed name change to Lexicon Pharmaceuticals, Inc. was approved by its shareholders at its annual shareholder meeting held on... More...>> |
| 04/24/2007 | 6:30AM | PRNUS | Lexicon Advances LX1031 for Irritable Bowel Syndrome Into Phase 1b Clinical Trial
THE WOODLANDS, Texas, April 24 /PRNewswire-FirstCall/ -- Following positive results from a Phase 1a study, Lexicon Genetics Incorporated (NASDAQ:LEXG) has initiated a Phase 1b clinical trial of its investigational new drug LX1031 for irritable bowel syndrome. LX1031 was found to be well-tolerated at all doses tested... More...>> |
| 04/23/2007 | 6:30AM | PRNUS | Lexicon to Present at the Morgan Stanley Global Healthcare Unplugged Conference
THE WOODLANDS, Texas, April 23 /PRNewswire-FirstCall/ -- Lexicon Genetics Incorporated (NASDAQ:LEXG) announced today that Arthur T. Sands, M.D., Ph.D., Lexicon's president and chief executive officer, will present at the Morgan Stanley Global Healthcare Unplugged Conference at the Ritz-Carlton in Key Biscayne, Florida... More...>> |
| 04/18/2007 | 5:00PM | PRNUS | Lexicon-Genentech Collaboration Yields Potential Therapeutic Targets
Data Presented at Society for Biomolecular Sciences Conference
THE WOODLANDS, Texas, April 18 /PRNewswire-FirstCall/ -- Lexicon Genetics Incorporated (NASDAQ:LEXG) announced that data was presented today highlighting potential therapeutic targets related to its collaboration with Genentech, Inc. at the Society for Biomolecular... More...>> |
| 04/17/2007 | 5:00PM | PRNUS | Lexicon Reports on Anti-Angiogenesis Target Discoveries
THE WOODLANDS, Texas, April 17 /PRNewswire-FirstCall/ -- Lexicon Genetics Incorporated (NASDAQ:LEXG) today presented results from the company's genetic screen to identify proteins involved in blood vessel formation and organization. These results were delivered in both a presentation and poster titled Large Scale Genetic... More...>> |
| 04/13/2007 | 6:30AM | PRNUS | Lexicon to Report First Quarter 2007 Financial Results on May 1, 2007; Conference Call and Webcast to Follow
THE WOODLANDS, Texas, April 13 /PRNewswire-FirstCall/ -- Lexicon Genetics Incorporated (NASDAQ:LEXG) will release its first quarter 2007 financial results on Tuesday, May 1, 2007 before the financial markets open. Lexicon management will hold a conference call to discuss the company's results and provide financial... More...>> |
| 03/21/2007 | 7:30AM | PRNUS | Lexicon Genetics Appoints Tamar Howson Executive Vice President of Business Development
THE WOODLANDS, Texas, March 21 /PRNewswire-FirstCall/ -- Lexicon Genetics Incorporated (NASDAQ:LEXG) today announced the appointment of Tamar D. Howson as executive vice president of business development, responsible for leading the company's pharmaceutical partnering and licensing efforts. She will be a member of... More...>> |
| 02/28/2007 | 6:30AM | PRNUS | Lexicon Genetics Elects Kathleen Wiltsey to Board of Directors
THE WOODLANDS, Texas, Feb. 28 /PRNewswire-FirstCall/ -- Lexicon Genetics Incorporated (NASDAQ:LEXG) announced today that Kathleen Wiltsey has been elected to its board of directors.
Ms. Wiltsey brings to Lexicon extensive biotechnology entrepreneurial experience in marketing and business development from her 14-year... More...>> |
| 02/26/2007 | 5:00PM | PRNUS | Lexicon Announces Executive Management Promotions
THE WOODLANDS, Texas, Feb. 26 /PRNewswire-FirstCall/ -- Lexicon Genetics Incorporated (NASDAQ:LEXG) announced today two promotions in the company's senior management team. Brian P. Zambrowicz, Ph.D. has been appointed executive vice president and chief scientific officer, from executive vice president of research... More...>> |
| 02/21/2007 | 6:00AM | PRNUS | Lexicon Genetics Reports 2006 Fourth Quarter and Full Year Financial Results
THE WOODLANDS, Texas, Feb. 21 /PRNewswire-FirstCall/ -- Lexicon Genetics Incorporated (NASDAQ:LEXG), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today reported financial results for the three months and year ended December 31, 2006.
"Lexicon has now advanced... More...>> |
| 02/07/2007 | 5:00PM | PRNUS | Lexicon to Report Fourth Quarter and Full Year 2006 Financial Results on February 21, 2007
Conference Call and Webcast to Follow
THE WOODLANDS, Texas, Feb. 7 /PRNewswire-FirstCall/ -- Lexicon Genetics Incorporated (NASDAQ:LEXG) will release its fourth quarter and year end 2006 financial results on Wednesday, February 21, 2007 before the financial markets open. Lexicon management will hold a conference call... More...>> |
| 01/30/2007 | 6:00AM | PRNUS | Lexicon Advances LX6171 for Cognitive Disorders into Phase 1b Clinical Trial
THE WOODLANDS, Texas, Jan. 30 /PRNewswire-FirstCall/ -- Lexicon Genetics Incorporated (NASDAQ:LEXG) announced today that it has initiated a Phase 1b clinical trial of LX6171, its oral drug candidate for the treatment of cognitive impairment associated with disorders such as Alzheimer's disease, schizophrenia and vascular... More...>> |
| 01/29/2007 | 4:30PM | PRNUS | Lexicon Genetics Changing Name, Refocusing Business to Achieve Goal of Advancing Ten Drug Candidates Into Human Clinical Trials
THE WOODLANDS, Texas, Jan. 29 /PRNewswire-FirstCall/ -- Lexicon Genetics Incorporated (NASDAQ:LEXG) announced today that it is changing its name to Lexicon Pharmaceuticals, Inc. to reflect that it is focusing its operations on drug discovery and development activities related to its 10to10 Program. The 10to10 Program... More...>> |
| 01/24/2007 | 6:00AM | PRNUS | Lexicon Genetics Initiates Clinical Trials of LX1031 for Irritable Bowel Syndrome
THE WOODLANDS, Texas, Jan. 24 /PRNewswire-FirstCall/ -- Lexicon Genetics Incorporated (NASDAQ:LEXG) announced today that it has initiated Phase 1 clinical trials of LX1031, its oral drug candidate for irritable bowel syndrome (IBS) and other gastrointestinal disorders. Irritable bowel syndrome is a common gastrointestinal... More...>> |
| 01/03/2007 | 5:00PM | PRNUS | Lexicon Genetics to Present at the 25th Annual JPMorgan Healthcare Conference
THE WOODLANDS, Texas, Jan. 3 /PRNewswire-FirstCall/ -- Lexicon Genetics Incorporated (NASDAQ:LEXG) announced today that Arthur T. Sands, M.D., Ph.D., Lexicon's president and chief executive officer, will present at the 25th Annual JPMorgan Healthcare Conference at The Westin St. Francis Hotel in San Francisco on Thursday... More...>> |
| 12/07/2006 | 5:00PM | PRNUS | Lexicon Genetics to Present at RBC Capital Markets Healthcare Conference
THE WOODLANDS, Texas, Dec. 7 /PRNewswire-FirstCall/ -- Lexicon Genetics Incorporated (NASDAQ:LEXG) announced today that Arthur T. Sands, M.D., Ph.D., president and chief executive officer, will participate in two panels at the RBC Capital Markets Healthcare Conference at The Westin, New York City on Thursday, December... More...>> |
| 12/05/2006 | 6:00AM | PRNUS | Lexicon Genetics Files Investigational New Drug Application for LX1031 in Irritable Bowel Syndrome
THE WOODLANDS, Texas, Dec. 5 /PRNewswire-FirstCall/ -- Lexicon Genetics Incorporated (NASDAQ:LEXG) announced today that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for LX1031, an internally-developed small molecule compound for gastrointestinal disorders... More...>> |
| 12/04/2006 | 6:30AM | PRNUS | Webcast Alert: Lexicon Genetics Incorporated Announces Webcast of Annual Analyst and Investor Luncheon
THE WOODLANDS, Texas, Dec. 4 /PRNewswire/ -- Lexicon Genetics Incorporated (NASDAQ:LEXG) announces Webcast, with the details described below.
What: Lexicon's senior management will provide a comprehensive update on
the company's clinical and preclinical programs at its Annual
Analyst and Investor... More...>> |
| 11/21/2006 | 6:00AM | PRNUS | Lexicon Genetics to Webcast Presentations at Upcoming Lazard and Piper Jaffray Investor Conferences
THE WOODLANDS, Texas, Nov. 21 /PRNewswire-FirstCall/ -- Lexicon Genetics Incorporated (NASDAQ:LEXG) announced today that its management will participate in the upcoming investor events listed below.
Arthur T. Sands, M.D., Ph.D., president and chief executive officer, will present at the Lazard Capital Markets Third... More...>> |
| 11/01/2006 | 5:00PM | PRNUS | Lexicon Genetics to Present at Rodman & Renshaw 8th Annual Healthcare Conference
THE WOODLANDS, Texas, Nov. 1 /PRNewswire-FirstCall/ -- Lexicon Genetics Incorporated (NASDAQ:LEXG) announced today that Alan J. Main, Ph.D., senior vice president of Lexicon Pharmaceuticals, will present at the Rodman & Renshaw 8th Annual Healthcare Conference at the New York Palace Hotel, New York City on Tuesday... More...>> |
|
|
|